<DOC>
	<DOCNO>NCT02115165</DOCNO>
	<brief_summary>Cabazitaxel new generation taxane high capacity blood-brain barrier cross limited peripheral neuro-toxicity , two major potential advantage patient advanced NSGCTs . Cabazitaxel broad vitro spectrum activity docetaxel . Taxanes demonstrate activity pre-treated GCTs part standard treatment , cabazitaxel yet test patient NSGCT .</brief_summary>
	<brief_title>A Prospective Study Cabazitaxel Patients With Non Seminomatous Germ-cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<criteria>Male patient age 15 year old Evidence advance NSGCT document either pathology elevate tumor marker ( AFP hCG ) compatible clinical presentation Primary site locate either testis , retroperitoneum mediastinum Progressive disease least 2 line chemotherapy advance NSGCT ( ie , nonstage I ) In case brain metastasis , confirm patient stable / control corticosteroid/anti seizure agents No progressive carcinoma within previous 5 year , except basalcell carcinoma skin Life expectancy &gt; /= 3 month Adequate hematologic function : Hemoglobin &gt; /= 10.0 g/dL Absolute neutrophil count &gt; /= 1.5 x 10 ^ 9/L , Platelet count &gt; /= 100 x 10 ^ 9/L , Adequate organ function Serum creatinine &lt; 1.5 x ULN . If serum creatinine 1.0 1.5 x ULN , creatinine clearance calculate ( measure ) accord CKDEPI formula ( see Appendix B ) &gt; 60 mL/min AST/SGOT ALT/SGPT &lt; /= 1.5 x ULN Bilirubin &lt; /= 1.5 x ULN Information deliver patient inform consent form sign patient legal representative Patient affiliate social security system beneficiary Patients receive anti cancer therapy within 4 week prior enrolment Previous radiotherapy within 4 week prior enrolment Serious uncontrolled concurrent medical illness History severe hypersensitivity reaction ( &gt; /= grade 3 ) polysorbate 80 contain drug taxanes Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 ( see Appendix A ) . A one week washout period necessary patient already treatment . Patient reproductive potential implementing accept effective method contraception 6 month last dose cabazitaxel . Active Grade &gt; /= 3 peripheral neuropathy Patients major surgery within 4 last week prior enrolment Uncontrolled cardiac arrhythmia , angina pectoris , and/or hypertension . History congestive heart failure ( NYHA III IV ) myocardial infarction within last 6 month also allow</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>